Category: CareFusion Corp.
ConvaTec is reportedly weighing a sale of the private-equity-owned medical device company next year, even as interest in a Medtronic-like inversion deal mounts from C.R. Bard, CareFusion and 3M.
Here's a look at some of the top Wall Street stories for medical device companies this week: FTC wants more data on Medtronic-Covidien deal, but analysts aren't worried; Greatbatch acquires Uruguay's CCC Medical Devices; T2 Biosystems IPO raises $57M for MRI-based diagnostics; Strong Q4, $750M buyback give CareFusion a boost; Baxano: Strong Q2, new patents can't appease Wall Street
CareFusion gains a couple points after posting a Street-beating 4th quarter and announcing a $750 million share repurchase program.
CareFusion (NYSE:CFN) posted a stellar 4th-quarter, posting double-digit growth in revenues and earnings and beating Wall Street's estimates.
The FDA wants CareFusion to stop selling its anesthesia breathing circuit and the Denver ascites shunt and percutaneous access kit until it applies for clearance for changes made to the devices and clears up some quality control issues at a plant in Illinois.
UPDATED July 24, 2014, with comment from CareFusion.
Here's a look at some of the top Wall Street stories for medical device companies this week: Wright Medical launches Infinity total ankle implant; Investors fire life science VC Burrill from his own fund; CareFusion hits new high, confirms layoffs and outsourcing to Mexico; Allergan urges shareholders to reject Valeant's $52B hostile takeover bid
Medtech giant CareFusion hits a new 52-week Wall Street high and confirms plans to fire nearly 400 employees as it moves manufacturing from New Jersey to Mexico.
Updated 6/24/2014 at 5:20 p.m. EST with comments from CareFusion.
Here's a look at some of the top Wall Street stories for medical device companies this week: Is Boston Scientific's peripherals buy bad news for Cardiovascular Systems?; M&A: Medtech makers use acquisitions to fill niches; Report: Deals in the medical device sector rose 200% in Q1; CareFusion plans $1B debt offering; Activist investor Oracle revives proxy war at Biolase.